Subjects must satisfy the following criteria to be enrolled in the study:
1. Age ≥ 18 years at the time of informed consent.
2. Signed written informed consent obtained prior to any study procedure.
3. Willing and able to adhere to the study visit schedule and other protocol
4. Relapsed and/or refractory aggressive B-cell NHL as defined:
1. Histologically confirmed DLBCL not otherwise specified, high-grade B-cell
lymphoma with MYC and BCL2 and/or BCL6 rearrangements with DLBCL histology
(HGBCL), transformed DLBCL from follicular (tFL) or marginal zone lymphoma
(tMZL), primary mediastinal B-cell lymphoma (PMBCL), or FL grade 3b (FL3B) AND
2. Have relapsed and/or refractory disease after at least 2 lines of systemic
therapy which must include at least one anthracycline and rituximab (or other
anti-CD20 monoclonal antibody).
Note: Lines of therapy will exclude those given for prior indolent lymphoma. It
is not required for subjects to have had anthracycline for their DLBCL if
received for indolent disease AND/OR
3. Have relapsed and/or refractory DLBCL failed to ASCT treatment. Note: ASCT
failure is defined as either failure to achieve an objective response (PR or
better), or disease progression after ASCT.
5. Positron emission tomography (PET)-positive disease as per the Lugano Classification.
6. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
7. Adequate organ function as detailed in the protocol.
8. Adequate vascular access for leukapheresis.
9. Willing and able to undergo tumor biopsies (in subjects with accessible disease).
10. Agree to not donate blood, organs, sperm or semen, and egg cells for usage in other
individuals as detailed in the protocol.
11. Female and male subjects agree to use effective contraception as detailed in the
The presence of any of the following will exclude a subject from enrollment:
1. Uncontrolled medical, psychological, familial, sociological, or geographical
conditions that do not permit compliance with the protocol, as judged by the
Investigator; or unwillingness or inability to follow the procedures required in the
2. Any condition including the presence of laboratory abnormalities, which places the
subject at unacceptable risk if he/she were to participate in the study.
3. Any condition that confounds the ability to interpret data from the study.
4. Central nervous system (CNS)-only involvement by malignancy (note: subjects with
pathologically-confirmed secondary CNS involvement are allowed).)
5. Prior CAR T- cell or genetically-modified T- cell therapy, or prior CD19- targeted
therapy (including, but not limited to, anti-CD19 mAbs or bispecific antibodies).)
6. Treatment with the following therapies or procedure within the specified period:
1. Therapeutic doses of corticosteroids (defined as > 20 mg/day prednisone or
equivalent) within 14 days before leukapheresis administration. Physiologic
replacement, topical, and inhaled steroids are permitted.
2. Cytotoxic chemotherapeutic agents (eg, doxorubicin, vincristine, gemcitabine,
oxaliplatin, carboplatin, etoposide) that are not considered lymphotoxic and
intrathecal therapy (IT) (see below) within 7 days of leukapheresis. Oral
chemotherapeutic agents, including lenalidomide and ibrutinib, are allowed if at
least 5 half-lives have elapsed prior to leukapheresis.
3. Lymphotoxic chemotherapeutic agents (eg, cyclophosphamide, ifosfamide,
bendamustine) within 4 weeks of leukapheresis.
4. Any experimental therapy within 8 weeks (for biologics) or 5 half-lives (for
small molecules) before leukapheresis
5. Immunosuppressive therapies within 4 weeks of leukapheresis (eg, calcineurin
inhibitors, methotrexate or other chemotherapeutics, mycophenolate, rapamycin,
immunosuppressive antibodies such as anti-TNF, anti-IL6, or anti-IL6R)
6. Donor lymphocyte infusions within 6 weeks of leukapheresis
7. Radiation within 6 weeks of leukapheresis. Subjects must have progressive disease
in irradiated lesions or have additional non-irradiated, PET-positive lesions to
be eligible. Radiation to a single lesion, if additional non-irradiated
PET-positive lesions are present, is allowed up to 14 days prior to
8. Autologous stem-cell transplant (SCT) (ie, Day 0 receipt of hematopoietic stem
cells) within 3 months of leukapheresis
9. Washout of prior therapy (eg, bridging therapy for disease control)
7. Active autoimmune disease requiring immunosuppressive therapy.
8. Allogenic SCT (ie, Day 0 receipt of hematopoietic stem cells) within 6 months of
leukapheresis or presence of ongoing symptoms or treatment for chronic graft-versus
host disease (GVHD).)
9. Hypersensitivity to fludarabine and/or cyclophosphamide.
10. Prior history of malignancies, other than studied NHL, unless the subject has been
free of the disease for ≥ 2 years except for the following non-invasive malignancies:
1. Basal or squamous cell carcinoma of the skin
2. Carcinoma in situ of the cervix or the breast
3. Incidental histologic finding of prostate cancer (T1a or T1b using the TNM
(tumor, nodes, metastasis) clinical staging system) or prostate cancer that is
4. Other completely resected stage 1 solid tumor with low risk for recurrence
11. Active hepatitis B, hepatitis C, or any human immunodeficiency virus (HIV) infection
at the time of screening.
12. Uncontrolled or active systemic fungal, bacterial, viral or other infection despite
appropriate anti-infection treatment at the time of leukapheresis or pre-treatment
13. History of any one of the following cardiovascular conditions within the 6 months
prior to screening: Class III or IV heart failure as defined by the New York Heart
Association, myocardial infarction, unstable angina, angioplasty or stenting, or other
clinically significant cardiac disease.
14. History or presence of clinically significant CNS pathology such as seizure disorder,
aphasia, stroke, severe brain injuries, dementia, Parkinson's disease, or cerebellar
disease. Presence of clinically active psychosis.
15. History of ≥ Grade 2 hemorrhage within 30 days of screening.
16. Pregnant or nursing (lactating) women.